Articles tagged with Breast Cancer Cells
Researchers discovered that breast cancer cells trigger the self-destruction of mutated BRCA1 proteins through ubiquitination, resulting in compromised tumor suppressor function. This process can be targeted for potential therapeutic treatment.
Researchers at Johns Hopkins Medicine have identified a chain reaction that shields breast cancer stem cells from chemotherapy, making them resistant to treatment. The discovery could lead to the development of drugs that block this pathway, improving chemotherapy effectiveness.
Researchers at UT Southwestern Medical Center found that cancer cells use the dynamin1 protein, once thought exclusive to neurons, to sustain rapid cell division and evade death signals. Aggressive cancer cells adapt neuronal mechanisms to thrive in a
A new study confirms PAK4's role in enabling pancreatic cancer cells to grow and spread, highlighting potential new targets for therapy. Researchers found a close relationship between PAK4 and the phosphoinositide 3-kinase pathway, which could lead to combination therapies targeting both.
A new study from Michigan Medicine identifies a protein in the microenvironment of metastatic breast cancer cells that promotes their spread. The researchers found that this protein, DDR2, plays a key role in fueling the growth and migration of cancer cells, and that inhibiting it may prevent metastasis.
A team of researchers has identified a long-lived type of stem cell in the breast that grows mammary glands during pregnancy and may be linked to high-risk breast cancer. The discovery reveals new insights into how cancers arise from long-lived stem cells.
Researchers from Mayo Clinic have quantified the numbers of various immune cells associated with the risk of developing breast cancer. The study found that women who later developed breast cancer showed lower amounts of antibody-producing immune cells in their breast tissue.
Researchers have found that somatostatin receptor sst2 antagonist tracers can target a greater number of sst2 sites in non-NET tumors than agonists. The study shows high binding of the antagonist in 12 breast cancers, all renal cell carcinomas, and 5 medullary thyroid cancers, while agonist binding was low or absent in these cases.
Scientists have created a 'map' linking cell shape to genes turned on and off, matching it to real disease outcomes. The map revealed key areas controlling gene activity, including a protein called NF-kappaB that drives cancer cell growth and spread.
A new laboratory technique allows for the indefinite growth of healthy and diseased cells, offering possibilities for living biobanks, personalized medicine, and novel cancer research. The method, known as conditional reprogramming, can grow million new cells in a week without genetic modification.
Researchers found inhibiting metabolic enzyme phosphoglycerate mutase 1 (PGAM1) sensitizes tumors to Olaparib, expanding cancer treatment options. Combining PGAM1 inhibitors with Olaparib suppresses tumor growth in BRCA-proficient cancers.
According to a study published in Journal of Thoracic Oncology, advanced stage Non-Small Cell Lung Cancer (NSCLC) patients receiving standard of care treatment have significantly longer overall survival rates compared to those not receiving treatment. This trend is observed across various stages of the disease.
Researchers at Massachusetts General Hospital have found that tumor necrosis factor receptor type II (TNFR2) may be a major target for immuno-oncology treatments. The team's findings suggest that blocking TNFR2 could restore the ability of a patient's immune system to attack tumors, while also directly killing cancer cells.
Massachusetts General Hospital investigators identified a protein called G3BP2 that helps maintain aggressive tumor-initiating cells in breast cancer. Compounds like C108 can reduce the survival of these cells and slow tumor growth.
Scientists have designed an antibody-based therapy targeting the functions of TGF-beta that cause cancer. The therapy showed promise by slowing down breast cancer tumor growth and metastasis when GARP was deleted from mice with mammary tumors.
Researchers identified LATS as a key player in breast cancer development and treatment. The enzyme's absence leads to increased luminal precursor cells, which can give rise to tumors, and stabilized proteins YAP and TAZ that boost cell proliferation.
The study reveals new ways in which receptor tyrosine kinases (RTKs) and phosphatases interact, with surprising effects on cancer progression. The researchers found that some phosphatases promote RTK signalling, while others activate it to a halt.
Scientists have identified the key molecule YAP that enables cancer cells to break free from their surroundings and continue growing and spreading. By understanding how YAP is controlled in cancer cells, researchers hope to find new ways to treat or prevent the spread of cancer.
Researchers have discovered how cancer cells convert into blood vessel-supporting cells that drive tumor growth. The process of epithelial-to-mesenchymal transition (EMT) sustains blood vessels and fuels tumor expansion.
Researchers from Ruhr-University Bochum found that capsaicin, an active ingredient in chilli peppers, inhibits the growth of triple-negative breast cancer cells by activating the TRPV1 receptor. The treatment also causes tumour cells to die and reduces their ability to form metastases.
The study estimates that about 3,000 tons of PHCZs lie in the sediment under lakes Michigan, Superior, and Huron, with Category 2 PHCZs likely from man-made sources. Most PHCZs, however, are believed to result from natural processes.
WPI researchers develop a liquid biopsy chip that can trap and identify metastatic cancer cells in small amounts of blood. The device uses antibodies attached to carbon nanotubes, which create an electrical signature that can be detected to identify captured cells.
A team of investigators found that breast cancer cells with a few defined molecular alterations can spread to organs and form aggressive metastasis without a primary tumor. Most early spread cells remain dormant until a growth switch is activated.
A UT Dallas biologist and his team discovered that NQO1 and HIF-1a, two enzymes previously linked to cancer cell survival, actually work in tandem to promote tumor growth. The researchers found that NQO1 binds to HIF-1a, stabilizing it and preventing its degradation.
A team of scientists tracked the genetics of disseminated tumour cells in breast cancer patients, finding they are genetically similar to the original tumour. This knowledge could help clinicians choose the most effective therapy, potentially leading to better outcomes and a more accurate prognosis.
New research reveals microRNAs play a vital role in regulating gene expression, influencing organismic development and disease. Studies have uncovered a vast network of miRNA families that target disparate gene pathways.
Researchers at Thomas Jefferson University discovered that a protein called TIGAR promotes the growth of breast cancer cells by altering cell metabolism, which could be targeted with existing drugs like metformin and doxycycline. These therapies have already passed safety testing in humans and may help reduce tumor growth.
Researchers at NUS have found that controlling TIP60 protein levels could prevent breast cancer cell spread. TIP60 interacts with DNMT1 and SNAIL2 to inhibit metastasis, suggesting a potential new strategy for treating various cancers.
Researchers have developed a method to measure the mechanical force that cancer cells exert on their fibrous surroundings. This study found that as cancerous cells migrate through 'cross-talk' with the matrix, it stiffens, causing the cell to pull harder and potentially promote metastasis.
Researchers found that triple-negative breast cancer cells are addicted to cystine and die rapidly when deprived of it, suggesting a potential new treatment. Cystine-blocking molecules may be effective in targeting this pathway, which is also used by other aggressive cancers.
Researchers found that regulatory T cells in tumors have distinct features and differences compared to normal tissue, making them potential biomarkers or therapeutic targets. The study aims to improve cancer immunotherapies by targeting specific molecules expressed by these immune cells.
Researchers at Texas A&M University found that breast cancer cells may evade treatment by consuming stem cells from bone marrow, making them difficult to kill. This mechanism could explain cancer recurrence and lead to new treatments, such as delivering toxic agents directly to cancer cells using stem cells as a delivery vehicle.
TGen researchers discovered that blocking nerve growth factor (NGF) signaling can reduce the potential of pancreatic cancer cells to invade surrounding nerves, leading to pain. The study found that NGF and its receptor TRKA are associated with perineural invasion, a key mechanism in the progression of pancreatic cancer.
Researchers found that high levels of Manganese Superoxide Dismutase (MnSOD) trigger aggressive breast cancer cell behavior. By targeting MnSOD, scientists hope to develop effective therapeutic strategies against triple-negative breast cancer.
Researchers silenced SIRT2 to accelerate the degradation of Slug protein, reducing tumor growth and invasiveness in basal-like breast cancer cells. The study revealed a direct relationship between SIRT2, Slug stability, and malignant behavior, providing new insights into treating aggressive basal-like breast cancers.
Researchers at Boston University School of Medicine have discovered a potential treatment option for ovarian cancer by combining calpeptin with epigenetic inhibitors. The therapy shows promise in killing cancer cells and preventing their growth, offering new hope for women affected by the disease.
Researchers from NUS have unraveled the molecular story of FHL2 and its relocation to the nucleus in response to ECM stiffness, influencing protein synthesis and cell proliferation. This study provides new insights into the regulation of cell growth in soft environments.
A multidisciplinary team has developed a new method to automate the screening of breast cancer histopathology images, improving detection rates. The technique uses image-processing methods to identify cancerous cells, overcoming challenges posed by clustered and vague boundaries.
A new study from the University of Manchester explains the process of post-breastfeeding tissue remodeling, discovering that milk-producing cells are transformed into cannibalistic cell-eaters. The study found a key role for the protein Rac1 in this cellular switch, which helps reshape the breast back to its normal state after weaning.
Researchers harness microRNA therapy to block movement of cancer cells from primary tumors, preventing fatal proliferation and metastasis. The study's results suggest a promising approach for human breast cancer treatment.
Researchers identified nuclear transport genes, particularly XPO1, as key players in tamoxifen resistance. Combining tamoxifen with selinexor improves sensitivity and prevents tumor recurrence.
Researchers found that CHD1-depleted human prostate cancer cells are hypersensitive to DNA breaks and chemotherapeutic drugs, including PARP inhibitors. This suggests CHD1 as a potential biomarker for targeted prostate cancer therapy.
Scientists combine immunotherapy with chemotherapy to destroy a majority of dormant cancer cells, preventing recurrence. The study shows that quiescent but not indolent cancer cells can evade immunotherapy, offering new hope for cancer treatment.
Researchers discovered that the experimental drug AMPI-109 works by flipping a molecular switch on PRL-3 enzyme, which initially puts cancer cells to 'sleep' and then leads to their death. This mechanism could sensitize triple-negative breast cancers to immunotherapy, offering new treatment options.
Researchers at UCF have discovered a way to kill spreading breast cancer cells using the peptide CT20. The therapy, called SEVA-108, targets metastatic cancer cells and has the potential to reduce traumatic side effects of traditional chemotherapies.
A new study of nearly 2,000 patients found that women with a specific pattern of gene activity were three times more likely to die from their breast cancers within 10 years. The research identified two genes, F12 and STC2, which may play a key role in releasing cancer cells from the glue that holds them in place.
Researchers propose that natural selection favors strong anti-cancer protection in small, critical organs like the heart and brain. The study suggests that these organs are more resistant to tumor formation due to their smaller size and importance for human survival.
New research suggests EBV infection may increase risk of developing breast cancer, particularly high-grade estrogen-receptor-negative disease. EBV binds to breast cells, causing them to take on stem cell characteristics and accelerating tumor formation.
Researchers discovered that cells from the same lot purchased from a cell bank exhibited vastly different responses to chemicals and had distinct genetic profiles. This finding raises concerns about the reliability of cell culture experiments, which rely on these cells as a foundation.
A team of researchers has obtained detailed structural information on KDM5 histone demethylase inhibitors, which could inform the design of more potent and selective anticancer drugs. The study found that these inhibitors can stop the growth of certain breast cancer cells, particularly those with specific genetic markers.
A new study found that an enriched hops extract activates a chemical pathway in cells that could help prevent breast cancer. The research discovered a compound called 6-prenylnarigenin (6-PN), which increased a detoxification pathway linked to a lower risk of breast cancer.
Researchers at CRG have discovered an active repression mechanism involving the progesterone receptor in hormone-dependent breast cancer cells, affecting 650 genes. The study identifies a protein FOXA1 that signals genes for repression by compacting chromatin and restricting gene access.
A new microfluidic device has been developed to study the effects of electric fields on cancer cells, effectively stopping their growth and spread. The device uses low-intensity, middle-frequency electric fields to preserve healthy cells.
A new treatment developed by UTSA researcher Matthew Gdovin can kill up to 95% of cancer cells in two hours using a single dose and a beam of light. The method involves injecting a chemical compound into the tumor and then exposing it to a beam of light, causing the cells to become acidic and commit suicide.
Mount Sinai scientists identified CBX8 as a protein that promotes tumor growth in the most lethal forms of breast cancer. This study highlights the need to focus on epigenetic factors and suggests new strategies against these aggressive cancers.
Researchers develop a revolutionary approach to cancer treatment that activates two drugs within the same cell at the same time, preventing resistance in aggressive cancers. By tracking cellular signals and molecular pathways, they discovered vulnerabilities to small molecule PI3K/AKT kinase inhibitors.
Research suggests that an extract from hops could help fend off breast cancer by boosting the cells' detoxification pathway, a process linked to a lower risk of developing breast cancer. The study found that one particular compound, 6-PN, had anti-cancer effects and may be a potential natural alternative to hormone replacement therapy.
Researchers identified denosumab as a potential non-surgical option to prevent breast cancer in women with elevated genetic risk. The study showed that the drug switched off cell growth and curtailed breast cancer development in laboratory models.
Researchers discovered a new signaling pathway that helps cancer cells cope with hypoxia, allowing them to thrive in low-oxygen environments. The study found that the enzyme protein-tyrosine phosphatase 1B (PTP1B) regulates tumor response to hypoxia by controlling oxygen consumption, potentially leading to novel treatments.
A new study has identified a connection between a cancer gene and the metabolic processes that fuel the rapid growth and movement of aggressive cancer cells. Researchers discovered that the RhoC gene regulates cell metabolism and energy production, driving cancer cells to move faster than normal.